C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 10:30 a.m. EST. This conference emphasizes the company's innovative approach to developing small-molecule medicines that selectively degrade disease-causing proteins.

The live webcast can be viewed on the company's website, with a replay available for two weeks post-event. C4 Therapeutics focuses on targeted protein degradation to improve treatment options for cancer and other diseases.

News Market Reaction – CCCC

+3.20%

+3.20% Session move

In the trading session that priced this news, CCCC gained 3.20%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the Company will present at the 40^th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 10:30 a.m. EST.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived on the C4T website for at least two weeks following the presentation.

About C4 Therapeutics
C4 Therapeutics (C4T) is a clinical-stage biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity. To learn more about C4 Therapeutics, visit www.c4therapeutics.com.

Investor Contact: 
Kendra Adams 
SVP, Communications & Investor Relations 
Kendra.Adams@c4therapeutics.com

Media Contact: 
Loraine Spreen 
Director, Corporate Communications & Patient Advocacy 
LSpreen@c4therapeutics.com

FAQ

When is C4 Therapeutics presenting at the J.P. Morgan Healthcare Conference?

C4 Therapeutics will present on January 10, 2022, at 10:30 a.m. EST.

Where can I watch the C4 Therapeutics conference presentation?

You can watch the presentation live on the C4 Therapeutics website under the 'Events & Presentations' section.

What is the focus of C4 Therapeutics?

C4 Therapeutics focuses on developing small-molecule medicines that selectively destroy disease-causing proteins.

What is the significance of the targeted protein degradation approach?

This approach may offer advantages like treating a broader range of diseases, reducing drug resistance, and minimizing side effects.

How long will the C4 Therapeutics presentation be available for replay?

The replay of the presentation will be available for at least two weeks after the event.